<DOC>
	<DOCNO>NCT01657942</DOCNO>
	<brief_summary>The hypothesis study focal treatment ExAblate MRgFUS potential effective non-invasive treatment low intermediate risk , organ-confined prostate lesion , low incidence morbidity . The study hypothesis test measure treatment-related safety initial effectiveness parameter ExAblate MRgFUS treat patient , describe .</brief_summary>
	<brief_title>Focal MR-Guided Focused Ultrasound Treatment Localized Low Intermediate Risk Prostate Lesions</brief_title>
	<detailed_description>Objective feasibility trial ass safety initial effectiveness ExAblate MRgFUS treatment low intermediate risk , localize ( organ confine ) prostate lesion . ExAblate treatment implement focal lesion-selective therapy , direct pre-defined volume ( ) /sector ( ) prostate , identify map biopsy multi-parametric MRI , rather whole gland hemi-ablation treatment . Safety : evaluate incidence severity adverse event associate ExAblate 's MRgFUS focal treatment low risk organ confine prostate lesion . The risk ExAblate treatment-related incontinence impotence also assess study . Effectiveness : determine lesion control effect ExAblate 's MRgFUS focal treatment low risk organ-confined prostate lesion ( confirm IMAGE-guided mapping biopsy result ) .</detailed_description>
	<criteria>Inclusion Criteria 1 . Male subject age 50 old . 2 . Biopsy proven adenocarcinoma prostate ( use IMAGEguided 14+ core mapping biopsy ) , target core need obtain 6 month prior schedule treatment . 3 . Patient low intermediate risk , earlystage organconfined prostate cancer ( T1a T2b , N0 , M0 ) voluntarily choose ExAblate thermal ablation noninvasive treatment , may currently watchful wait active surveillance need imminent radical therapy . 4 . Patient PSA less equal 20 ng/mL 5 . Gleason score 6 ( 3 + 3 ) 7 ( 4 + 3 3 + 4 ) , base mapping prostate biopsy , 15mm cancer maximal linear dimension single core . 6 . Single hemilateral index Gleason 7 Gleason 6 lesion , identify prostate base biopsy map support MRI ; may secondary Gleason 6 lesion ipsilateral contralateral side confirm biopsy and/or MRI . 7 . Gleason 7 Gleason 6 tumor must MRI visible : 1 . In event tumor contact capsule , length contact â‰¤ 5 mm , axial image . 2 . Largest image dimension cancerous find &lt; 20mm 8 . No definite evidence extracapsular extension seminal invasion MRI 9 . Patient eligible spinal/epidural anesthesia ( planned procedure ) , general anesthesia ( case complication , require intervention ) . 10 . Patient willing able give consent attend study visit complete questionnaire define protocol 11 . Tumor distance , include tumor free margin , 40mm rectal wall . Exclusion Criteria 1 . ASA status &gt; 2 2 . Contraindications MRI 2.1 Claustrophobia 2.2 Implanted ferromagnetic material foreign object 2.3 Known intolerance MRI contrast agent 3 . Severely abnormal coagulation ( INR &gt; 1.5 ) 4 . Patients unstable cardiac status include : 4.1 Unstable angina pectoris medication 4.2 Patients document myocardial infarction within 40 day prior enrollment 4.3 Congestive heart failure NYHA class IV 4.4 Patients unstable arrhythmia status , already antiarrhythmic drug 5 . Severe hypertension ( diastolic BP &gt; 100 medication ) 6 . Severe cerebrovascular disease ( multiple CVA CVA within 6 month ) 7 . History orchiectomy , PCaspecific chemotherapy , brachytherapy , cryotherapy , Photodynamic therapy radical prostatectomy treatment prostate cancer ; prior radiation therapy pelvis prostate cancer malignancy . 8 . Patient medication affect PSA last 3 month prior MRgFUS treatment ( Androgen Deprivation Treatment ; alpha reductase inhibitor ) 9 . Patients lesion Gleason 7 great outside plan treatment area . 10 . Individuals able willing tolerate require prolonged stationary supine position treatment ( approximately 3 hr . sonication time ) 11 . Any rectal pathology , anomaly previous treatment , could change acoustic property rectal wall prevent safe probe insertion ( e.g. , stenosis , fibrosis , inflammatory bowel disease , etc ) . 12 . Any spinal pathology prevent safe administration epidural/spinal anesthesia 13 . Identified calcification 2 mm large diameter neighbor rectal wall ( distance le 5 mm ) interfere acoustic beam path . 14 . Lower limb musculoskeletal fixed deformity prevent probe insertion patient position procedure . 15 . Prostate multiple cystic lesion . 16 . Evidence distant prostate cancer , i.e. , include lymph node and/or metastasis cancer image 17 . Bladder cancer 18 . Urethral stricture/bladder neck contracture 19 . Active UTI 20 . Prostatitis NIH category I , II III . 21 . Compromised renal function 22 . Implant near ( &lt; 1 cm ) prostate 23 . Interest future fertility 24 . Current participation another clinical investigation medical device drug participate study within 30 day prior study enrollment .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>MRgFUS</keyword>
	<keyword>Prostate</keyword>
	<keyword>Low Intermediate Risk Prostate Lesions</keyword>
	<keyword>Focal Prostate treatment</keyword>
	<keyword>InSightec</keyword>
	<keyword>ExAblate</keyword>
	<keyword>Non-invasive</keyword>
	<keyword>Gleason 6 Gleason 7</keyword>
	<keyword>Prostate cancer</keyword>
</DOC>